ATE288483T1 - Nicht-verbreitendes lebendes herpesvirusvakzin - Google Patents

Nicht-verbreitendes lebendes herpesvirusvakzin

Info

Publication number
ATE288483T1
ATE288483T1 AT93915729T AT93915729T ATE288483T1 AT E288483 T1 ATE288483 T1 AT E288483T1 AT 93915729 T AT93915729 T AT 93915729T AT 93915729 T AT93915729 T AT 93915729T AT E288483 T1 ATE288483 T1 AT E288483T1
Authority
AT
Austria
Prior art keywords
vaccine
pct
live
pseudorabies virus
mutant
Prior art date
Application number
AT93915729T
Other languages
English (en)
Inventor
Nicolaas Visser
Woensel Petrus Alphonsus M Van
Thomas Christoph Mettenleiter
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE288483T1 publication Critical patent/ATE288483T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93915729T 1992-07-30 1993-06-28 Nicht-verbreitendes lebendes herpesvirusvakzin ATE288483T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92202370 1992-07-30
PCT/EP1993/001661 WO1994003595A1 (en) 1992-07-30 1993-06-28 Non-shedding live herpesvirus vaccine

Publications (1)

Publication Number Publication Date
ATE288483T1 true ATE288483T1 (de) 2005-02-15

Family

ID=8210818

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93915729T ATE288483T1 (de) 1992-07-30 1993-06-28 Nicht-verbreitendes lebendes herpesvirusvakzin

Country Status (7)

Country Link
US (1) US5626850A (de)
EP (1) EP0606437B1 (de)
JP (1) JPH07500972A (de)
AT (1) ATE288483T1 (de)
AU (1) AU4560693A (de)
DE (1) DE69333751T2 (de)
WO (1) WO1994003595A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE181108T1 (de) 1991-08-26 1999-06-15 Immuno Ag Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus
TW289731B (de) * 1992-07-09 1996-11-01 Akzo Nv
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
US5612215A (en) * 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
EP0689603A1 (de) * 1993-03-19 1996-01-03 Cantab Pharmaceuticals Research Limited Defektiver mutanter nicht-retroviraler virus (2.b.hsv) zum impstoff
EP0659885A1 (de) * 1993-12-21 1995-06-28 Akzo Nobel N.V. Impstoffe gegen von Antikörper abhängende Vergrösserung (ADE) der Virus-Infektivität
WO1995030018A2 (en) * 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
EP0693551A1 (de) 1994-07-18 1996-01-24 Akzo Nobel N.V. gD-Negative Rinder-Herpesvirus Mutanten, mit der Fähigkeit zur direkten Zell zu Zell Übertragung
GB9415369D0 (en) * 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
JPH11500014A (ja) * 1995-02-21 1999-01-06 キャンタブ ファーマシューティカルズ リサーチ リミティド ウイルス調製物、ベクター、免疫原、及びワクチン
DE19626614A1 (de) * 1996-07-02 1998-01-08 Immuno Ag Komplex aus Antigen und Zellbestandteil, Impfstoffzusammensetzung, welche den Komplex enthält, pharmazeutische Präparation sowie Verfahren zur Herstellung des Komplexes
US6399354B1 (en) 1998-07-31 2002-06-04 President And Fellows Of Harvard College Replication-competent virus expressing a detectable fusion protein
EP1143047B1 (de) 1999-09-29 2015-11-04 Shin-Etsu Handotai Co., Ltd. Verfahren zur herstellung eines siliciumwafer
CN103468645B (zh) * 2013-08-30 2016-08-10 北京中联康生物科技股份有限公司 伪狂犬病毒、伪狂犬病疫苗及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE194657T1 (de) * 1990-09-25 2000-07-15 Cantab Pharma Res Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff
US5240703A (en) * 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof

Also Published As

Publication number Publication date
JPH07500972A (ja) 1995-02-02
WO1994003595A1 (en) 1994-02-17
EP0606437B1 (de) 2005-02-02
DE69333751T2 (de) 2005-12-29
US5626850A (en) 1997-05-06
AU4560693A (en) 1994-03-03
DE69333751D1 (de) 2005-03-10
EP0606437A1 (de) 1994-07-20

Similar Documents

Publication Publication Date Title
ATE288483T1 (de) Nicht-verbreitendes lebendes herpesvirusvakzin
GB9105383D0 (en) An immunotherapeutic for cervical cancer
ZA934882B (en) Vaccines against aujeszkyu's disease and other animal diseases containing pseudorabies virus mutants
ES8505719A1 (es) Procedimiento de preparar mutantes de delecion vivos y metodo de preparar vacunas
AU585126B2 (en) Recombinant herpes simplex viruses, vaccines and methods
FR2727689B1 (de)
ES8705036A1 (es) Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
ATE239036T1 (de) Rekombinantes core-streptavidin
IL77694A (en) Canine parvovirus vaccines comprising viruses of the canine parvovirus strain 154 or viruses derived therefrom by additional cell culture passaging
DE69929530D1 (de) Attenuierte pferdeherpesvirus
AU4334193A (en) Infectious bovine rhinotracheitis virus mutants and vaccines
YU49995A (sh) Polinukleotidna vakcina za virus herpesa
YU200091A (sh) Delecioni mutanti ahasarezistentni na herbicide
DE69417717D1 (de) Impstoff zum Schutze von Pferden gegen Pferdeherpesvirus-Infektionen
ES2074965A1 (es) Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen.
Hammerberg DETECTION OF A t‐COMPLEX ANTIGEN BY SECONDARY CELL‐MEDIATED LYMPHOCYTOTOXICITY
Grabstein et al. Regulation of Murine B-Cell Growth in Vitro by Infection with a Retroviral Vector Containing the Murine IL-1R
NO941544L (no) Rekombinant kjerne-streptavidin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties